ER+ and PR+ Breast Cancer: Key Statistics and Molecular Insights
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
Nature2 个月
An issue of tissues: divining the split personalities of selective estrogen receptor modulators
Figure 1: Nuclear receptor co-regulators modulate the transcriptional potential of estrogen receptor activated ... ER signaling pathways to confer a selective advantage in tumor progression.
pharmaphorum6 天
Pfizer's new drug data in breast cancer draws muted response
Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...
Nasdaq6 天
Arvinas and Pfizer Announce Positive Phase 3 VERITAC-2 Trial Results for Vepdegestrant in ...
Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the ...